NO20065499L - Kontroll av gjennombruddsblodning i utvidede hormonelle svangerskapsforebyggende regimer - Google Patents

Kontroll av gjennombruddsblodning i utvidede hormonelle svangerskapsforebyggende regimer

Info

Publication number
NO20065499L
NO20065499L NO20065499A NO20065499A NO20065499L NO 20065499 L NO20065499 L NO 20065499L NO 20065499 A NO20065499 A NO 20065499A NO 20065499 A NO20065499 A NO 20065499A NO 20065499 L NO20065499 L NO 20065499L
Authority
NO
Norway
Prior art keywords
control
hormonal contraceptive
breakthrough bleeding
contraceptive regimens
extended
Prior art date
Application number
NO20065499A
Other languages
English (en)
Other versions
NO341685B1 (no
Inventor
Andreas Sachse
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065499(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20065499L publication Critical patent/NO20065499L/no
Publication of NO341685B1 publication Critical patent/NO341685B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Den foreliggende oppfinnelse angår et fleksibelt utvidet anvendelsesregime for et hormonelt svangerskapsforebyggende middel som er nyttig til å kontrollere blødningsproblemer forbundet med fast utvidet anvendelse av hormonelle svangerskapsforebyggende midler, og en farmasøytisk pakke som inneholder det aktuelle hormonelle svangerskapsforebyggende midlet.
NO20065499A 2004-04-30 2006-11-28 Kontroll av gjennombruddsblødning i utvidede hormonelle svangerskapsforebyggende regimer NO341685B1 (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10
PCT/EP2005/004777 WO2005105103A2 (en) 2004-04-30 2005-04-29 Management of breakthrough bleeding in extended hormonal contraceptive regimens

Publications (2)

Publication Number Publication Date
NO20065499L true NO20065499L (no) 2006-11-29
NO341685B1 NO341685B1 (no) 2017-12-18

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065499A NO341685B1 (no) 2004-04-30 2006-11-28 Kontroll av gjennombruddsblødning i utvidede hormonelle svangerskapsforebyggende regimer

Country Status (29)

Country Link
US (3) US8163721B2 (no)
EP (1) EP1747001B1 (no)
JP (4) JP2007535519A (no)
KR (4) KR20160150113A (no)
CN (1) CN103127156A (no)
AR (1) AR048722A1 (no)
AU (1) AU2005237255B2 (no)
BR (1) BRPI0510493A (no)
CA (1) CA2562296A1 (no)
CR (1) CR8709A (no)
DK (1) DK1747001T3 (no)
EA (2) EA031227B1 (no)
EC (1) ECSP066999A (no)
ES (1) ES2704999T3 (no)
HU (1) HUE041475T2 (no)
IL (1) IL178458A (no)
LT (1) LT1747001T (no)
MX (1) MXPA06012567A (no)
MY (1) MY151322A (no)
NO (1) NO341685B1 (no)
NZ (1) NZ586107A (no)
PA (1) PA8631801A1 (no)
PE (1) PE20060467A1 (no)
SG (2) SG10201701904TA (no)
SI (1) SI1747001T1 (no)
SV (1) SV2006002100A (no)
TW (1) TWI374735B (no)
UY (1) UY28875A1 (no)
WO (1) WO2005105103A2 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
CA2736707A1 (en) * 2008-09-16 2010-03-25 Playtex Products, Llc Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
ES2795455T3 (es) 2008-10-08 2020-11-23 Agile Therapeutics Inc Suministro transdérmico
WO2010042607A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc Transdermal delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EA035687B1 (ru) 2015-06-18 2020-07-27 Эстетра Спрл Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент
DK3310345T3 (da) 2015-06-18 2021-05-25 Estetra Sprl Orodispersibel tablet indeholdende estetrol
EP3310346B1 (en) 2015-06-18 2021-03-24 Estetra SPRL Orodispersible tablet containing estetrol
UA123098C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
HRP20240121T8 (hr) * 2015-06-23 2024-05-10 Laboratorios Leon Farma Sa Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
NZ752916A (en) 2016-09-30 2022-09-30 Takeda Pharmaceuticals Co Methods of treating uterine fibroids and endometriosis
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) * 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
WO1993013801A1 (en) 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
JP2000515890A (ja) 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション プロゲスチンとエストロゲンとの混合剤からなる一相性避妊法およびキット
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
DK1598069T3 (da) 1999-08-31 2009-07-06 Bayer Schering Pharma Ag Farmaceutisk præparat af ethinylestradiol og drospirenon til anvendelse som præventionsmiddel
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
EA031227B1 (ru) 2018-12-28
EA016625B1 (ru) 2012-06-29
ECSP066999A (es) 2006-12-29
AU2005237255B2 (en) 2011-07-07
MY151322A (en) 2014-05-15
SG152288A1 (en) 2009-05-29
NO341685B1 (no) 2017-12-18
DK1747001T3 (en) 2019-02-04
US20050250747A1 (en) 2005-11-10
BRPI0510493A (pt) 2007-11-13
JP6153967B2 (ja) 2017-06-28
US8163721B2 (en) 2012-04-24
TW200603781A (en) 2006-02-01
EA201200377A1 (ru) 2012-08-30
JP2007535519A (ja) 2007-12-06
HUE041475T2 (hu) 2019-05-28
JP2013018787A (ja) 2013-01-31
CR8709A (es) 2007-08-28
JP2015187157A (ja) 2015-10-29
KR20070004919A (ko) 2007-01-09
LT1747001T (lt) 2019-01-25
KR101812160B1 (ko) 2017-12-27
EA200601908A1 (ru) 2007-04-27
EA201200377A8 (ru) 2018-01-31
KR20130022425A (ko) 2013-03-06
NZ586107A (en) 2012-05-25
UY28875A1 (es) 2005-11-30
IL178458A (en) 2016-08-31
WO2005105103A2 (en) 2005-11-10
SG10201701904TA (en) 2017-05-30
CA2562296A1 (en) 2005-11-10
SV2006002100A (es) 2006-02-15
CN103127156A (zh) 2013-06-05
PE20060467A1 (es) 2006-06-11
IL178458A0 (en) 2008-04-13
EP1747001B1 (en) 2018-10-10
PA8631801A1 (es) 2006-11-09
KR20160150113A (ko) 2016-12-28
SI1747001T1 (sl) 2019-02-28
AU2005237255A1 (en) 2005-11-10
ES2704999T3 (es) 2019-03-21
KR20150058555A (ko) 2015-05-28
JP2017048253A (ja) 2017-03-09
MXPA06012567A (es) 2006-12-15
EP1747001A2 (en) 2007-01-31
TWI374735B (en) 2012-10-21
JP6134491B2 (ja) 2017-05-24
US20150174142A1 (en) 2015-06-25
AR048722A1 (es) 2006-05-17
US20120202779A1 (en) 2012-08-09
WO2005105103A3 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
NO20065499L (no) Kontroll av gjennombruddsblodning i utvidede hormonelle svangerskapsforebyggende regimer
MXPA05011679A (es) Derivados de hidroxibifenilcarbaldehido oxima y su uso como agentes estrogenicos.
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
EP1906968A4 (en) NEW SCHEMES FOR ORAL MONOPHASIC CONTRAZEPTIVA
IL177483A0 (en) Means for transdermal administration of nicotine
DK1792927T3 (da) Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
NO20045217L (no) Anvendelse av tio-oxindolderivater for behandling av hormon relaterte tilstander
DK1732921T3 (da) Thiomidderivater som progesteronreceptormodulatorer
NO20076683L (no) Cyanopyrrol-sulfonamid progesteron reseptormodulatorer og deres anvendelse
EA200602156A1 (ru) Новая комбинация ингибитора iтока синусового узла и кальциевого ингибитора и фармацевтические композиции, её содержащие
MXPA05008347A (es) Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis.
DK1635843T3 (da) Terapi, der omfatter dienogest for hormonerstatning og depression
ATE448215T1 (de) Selektive östrogen-rezeptor-modulatoren
UA91190C2 (ru) Контроль прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов
DE602005011029D1 (de) Therapeutisches mittel zur behandlung von plasmazellneoplasien
NO20030606D0 (no) Modifisert gj¶r og anvendelser derav, n¶rmere bestemt for fremstilling avsteroidderivater
项俐 My prince
王瑛 Auld Lang Syne
FR2842539B1 (fr) Support destine a etre silicone par des silicones(ltc)
Tanaka The Origin and the Future of Macromolecule Ionization by Laser Irradiation
刘军 A Celebration of Human Nature
古典 Inspired by Love
Tu The Transmission of the Sagely Learning as Perceived by Liu Zongzhou

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE